Hanmi Partners RAF inhibitor HM95573 with Genentech in a deal worth US$910 M
By Jawala Prasad
Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)
Published: 12 Oct-2016
DOI: 10.3833/pdr.v2016.i10.2200 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Adding to its spree of out-licensing deals, Hanmi has convinced oncology leader Roche to partner in developing its early phase pan-RAF (rapidly accelerated fibrosarcoma) inhibitor, HM95573, in a deal worth up to US$910 M including an upfront payment of US$80M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS